Ekstrak botani, protein laut, dan bahan aktif spesialti Jepang
59 bahan.
Japanese cosmetic raw materials occupy a distinctive position in the global beauty supply chain, prized by formulators in Seoul, New York, Paris, and Shanghai for their combination of botanical purity, fermentation craftsmanship, and clinical-grade documentation. From Hokkaido birch sap and Yamagata safflower to Okinawan sea grape (umi-budo) extracts and Kagoshima volcanic clay, the country sources premium actives from farms, coastal waters, and research labs that have been refining extraction methods for generations. Japan ranks among the world's top three exporters of high-purity hyaluronic acid, fermentation-derived peptides, and rice-bran lipids, and its INCI-listed materials regularly anchor the prestige tier of K-beauty, J-beauty, and increasingly clean-beauty launches in Europe.
The heritage runs deep. Edo-period beauty rituals codified the use of camellia (tsubaki) seed oil, rice-bran (komenuka) emulsions, and Uji matcha pastes long before modern surfactant chemistry existed. Twentieth-century pioneers such as Shiseido, Kose, and Pola industrialized these botanical traditions and pioneered fermented yeast filtrates in the 1970s — a category Galactomyces and Pitera-style ferments still dominate today. Marine collagen, originally a by-product of Japan's vast fisheries industry, was clinically formalized in the 1990s by Niigata- and Hokkaido-based suppliers who developed low-molecular-weight peptides specifically for transdermal absorption. Even traditional sake-brewery towns such as Nada (Hyogo) and Fushimi (Kyoto) became cosmetic ingredient hubs after Sake Lees (sake-kasu) extracts were proven to brighten and soften skin.
In the modern market, Japan's cosmetic raw material industry is led by Nippon Fine Chemical, Kao Chemical, Ajinomoto's amino acid division, Nikko Chemicals (NIKKOL Group), Maruzen Pharmaceuticals (botanical extracts), Ichimaru Pharcos (plant ferments), Arysta Health & Nutrition Sciences, and Sansho — supported by hundreds of regional specialists in Toyama (kampo), Shizuoka (tea catechins), and Kagoshima (camellia, sweet potato). Most reputable manufacturers operate under ISO 22716 GMP, with adoption rates above 80% among export-oriented suppliers as of 2026. Many also hold ISO 9001, ISO 14001, EcoCert / COSMOS approvals for their botanical lines, and Halal certification from JAKIM-accredited Japanese auditors. Patent filings for fermentation-derived actives have grown roughly 12% annually since 2020, reflecting renewed R&D focus on microbiome, post-biotic, and exosome-style ingredients.
For overseas buyers, sourcing from Japan typically means a longer onboarding cycle (8–14 weeks for samples, technical data sheets, COA, allergen declarations, and INCI confirmation) but markedly higher batch-to-batch consistency than emerging-market alternatives. Minimum order quantities are flexible: small specialty houses accept 5–10 kg trial lots, while industrial suppliers default to 100–500 kg. Buyers should plan for documentation in Japanese-English bilingual format, request CITES and IUCN screening for any wild-harvested marine or botanical inputs, and confirm whether the active is supplied as a finished extract or a base requiring dilution. Quasi-drug (iyakubugaihin) actives such as tranexamic acid, arbutin, or 4MSK require additional PMD Act paperwork if the buyer plans to register a quasi-drug product in Japan.
To explore this catalog, start with our curated Cosmetic Raw Materials sourcing index, then drill down by botanical, marine, fermented, or quasi-drug active. Related categories worth visiting include Marine Functional ingredients (for fucoidan and proteoglycan suppliers), Traditional Materials (for sake, koji, and rice-derived bases), and the Cosmetics glossary (for INCI definitions and regulatory mapping). Most listed suppliers ship globally and accept sample requests directly through this platform.
Pilihan editor untuk pengunjung pertama kategori ini.
Cosmetic raw materials sold from Japan must align with the buyer's destination market: EU buyers should confirm CosIng listing, REACH registration where applicable, and CMR/endocrine-disruptor screening; US buyers should verify MoCRA Facility Registration of the Japanese manufacturer if the ingredient is shipped as a finished cosmetic component, and confirm the supplier's adverse-event reporting policy. China's IECIC 2021 catalog still excludes a number of Japan-popular actives (some fermentation derivatives, certain marine peptides) — buyers planning NMPA filings should pre-screen INCI names against the latest IECIC update. Within Japan, ordinary cosmetic ingredients are governed by the Pharmaceuticals and Medical Devices Act (PMD Act, 薬機法) under the cosmetic category, which permits self-certification of formulations within a positive/negative list framework. However, quasi-drug actives (iyakubugaihin, 医薬部外品) such as tranexamic acid, arbutin, niacinamide above standard concentrations, and most whitening or anti-acne claims require pre-market approval. Buyers should request the supplier's Japan Cosmetic Industry Association (JCIA) self-certification documentation and, where relevant, a Japan Standards of Cosmetic Ingredients (JSCI) reference.
Most Japanese botanicals listed in this catalog already appear in CosIng (EU INCI database) and have established US use history. China NMPA registration is the strictest gate; ask suppliers for IECIC listing status before quoting for the China market.
Sumber
Most Japanese cosmetic ingredient suppliers quote 1–10 kg minimums for liquid extracts and 5–25 kg for powdered actives. Premium proprietary actives (NSK-SD, fucoidan-based, pearl proteins) often start at 5 kg with R&D samples available.
Sumber
Klaim pengetahuan industri — belum disandarkan pada satu sumber primer
Japanese suppliers typically emphasize traceability to specific prefectures, longer manufacturing history (often 50–100+ years), and strict adherence to JCIA's Japan Standards of Cosmetic Ingredients (JSCI). Many also hold ISO 22716 (cosmetic GMP) and supply documentation in English.
Sumber
Yes. Quasi-drug actives (薬用成分) like albutin (arbutin), tranexamic acid, and m-tranexamic acid are widely supplied by Japanese OEMs. Note that quasi-drug claims (e.g., whitening, anti-wrinkle) only apply when sold under Japan's PMD Act; for overseas markets, claim wording must comply with local cosmetics law.
Sumber
Standard documentation includes: INCI declaration, certificate of analysis (heavy metals, microbiology), allergen statement (EU 26 fragrance allergens), animal-origin/BSE/TSE statement, GMO statement, and (for proprietary actives) trademark licensing terms. ISO 22716 GMP certificate is increasingly expected for EU shipments.
Sumber